Epitherapeutics ApS
Epitherapeutics is a leading epigenetic drug discovery company with a focus on oncology and with several programs in lead optimization
- Stage Product In Development
- Industry Biotechnology
- Location 2100 Copenhagen, Capital Region of Denmark, Denmark
- Currency USD
- Founded October 2008
- Employees 17
- Website epitherapeutics.dk
Company Summary
EpiTherapeutics is developing novel innovative cancer drugs based on world leading research by Professor Kristian Helin. EpiTherapeutics' development programs are focused on epigenetic enzymes involved in cancer (KDMs, KMTs).Most progressed program is in late lead optimization. EpiTherapeutics has a strong investor base including Novo Seeds, SEED Capital, Lundbeckfond Emerge, Merck Serono Ventures and Astellas Venture Management.
Team
-
Martin BondeCEO
Serial entrepreneur, founded and managed several companies in Denmark and the US (NatImmune A/S, Arpida A/S, Combio A/S, CelTor Inc., Torsana Biosensor)
Fronted several successful exits over the last decade (NatImmune A/S to IPC, Combio A/S to Arpida AG, Torsana Biosensor A/S to Celtor Inc) as well as heading out-licensing, acquisitions, in-licensing etc.
Advisors
-
Wiggin&DanaLawyerUnconfirmedErnst&YoungAccountantUnconfirmed
Previous Investors
-
Novo Seeds, SEED Capital, Lundbeckfond EmergeUnconfirmedMerck- Serono Ventures, Astellas VentureUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.